Kyntra Bio
KYNB
201 hedge funds and large institutions have $2.63B invested in Kyntra Bio in 2018 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 73 increasing their positions, 44 reducing their positions, and 34 closing their positions.
99% more call options, than puts
Call options by funds: $61.7M | Put options by funds: $31M
66% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 44
44% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 34
7% more funds holding
Funds holding: 187 → 201 (+14)
0.02% more ownership
Funds ownership: 2.65% → 2.67% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
23% less capital invested
Capital invested by funds: $3.39B → $2.63B (-$766M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$27.3M |
| 3 |
Janus Henderson Group
London,
|
+$23.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15M |
| 5 |
Bank of New York Mellon
New York
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$163M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$29M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$22.2M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$19.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.1M |
KYNB Hedge Fund Activity: Q4 2018 in Review
201 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2018, worth a combined $2.63B — down 23% from $3.39B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new KYNB positions and 34 closed out — a net gain of 15 holders — while 73 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $163M sold.
- 201 institutional investors held Kyntra Bio (KYNB) as of Q4 2018, up from 187 in Q3 2018.
- Funds reported $2.63B of Kyntra Bio stock for Q4 2018, down 23% quarter-over-quarter.
- 49 funds opened new Kyntra Bio positions in Q4 2018 and 34 closed out, a net change of +15 holders.
- The largest Kyntra Bio buyer in Q4 2018 was Fidelity Investments, an estimated $35M added.
- The largest Kyntra Bio seller in Q4 2018 was Hillhouse Investment Management, an estimated $163M sold.
Based on aggregated 13F filings for Q4 2018.